Metellus

Metellus is a private investment office based in Zurich and London, specialised in alternative investments (private equity, venture capital, real estate) and direct investments in technology and life sciences. Metellus takes an active ownership role to enhance value creation and is actively involved in the management of a diverse portfolio of investments in private equity and venture capital. Metellus is a member of SECA, the Swiss Private Equity & Corporate Finance Association.

Michael Albisser

CFO

Boris Battistini

VP of Venture Capital and Private Equity

4 past transactions

QuantalRF

Series C in 2022
QuantalRF AG operates as a RF semiconductor company that develops transformative wireless communication solutions. The company offers front-end IC parts, such as power amplifiers, low noise amplifiers, and on-chip filters that offers communication systems including Wi-Fi 6/6e and 5G UHB. QuantalRF AG was formerly known as DockOn AG .The company was founded in 2008 and is based in Zurich, Switzerland.

QuantalRF

Series B in 2020
QuantalRF AG operates as a RF semiconductor company that develops transformative wireless communication solutions. The company offers front-end IC parts, such as power amplifiers, low noise amplifiers, and on-chip filters that offers communication systems including Wi-Fi 6/6e and 5G UHB. QuantalRF AG was formerly known as DockOn AG .The company was founded in 2008 and is based in Zurich, Switzerland.

Revolo Biotherapeutics

Series B in 2020
Revolo Biotherapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory and immunological diseases, such as asthma, atopic dermatitis, and inflammatory bowel disease. The company's approach is grounded in the natural mechanisms employed by Mycobacterium tuberculosis to evade the host immune system, allowing it to suppress inflammatory responses. Unlike existing treatments that aim to suppress the immune system and often require chronic dosing with significant side effects, Revolo's immune-resetting therapies have shown promise in preclinical and human studies by safely transitioning the immune system from a pro-inflammatory state to a regulatory one. This novel strategy aims to induce long-term disease remission without the adverse effects typically associated with conventional therapies. Founded in 2001 and based in London, Revolo Biotherapeutics is dedicated to transforming the treatment landscape for patients suffering from allergic and immune-mediated conditions.

iZettle

Seed Round in 2010
iZettle is reinventing technologies and banking services that help small-business owners live better, work less and earn more. Based in Stockholm, the financial technology company revolutionized mobile payments in 2010 with the world’s first mini chip card reader and software for mobile devices. Today, small-business owners around the world use iZettle’s powerfully simple services to improve the speed and ease of payments at checkout, business management, sales analytics, customer engagement, and funding